Physician profile
Mohsen Zena
NPI 1548436033
$4,046.20
in general payments reported to CMS, 2019-2025
39 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $115 · 2021: $190 · 2022: $482 · 2023: $976 · 2024: $792 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $718.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $363.38 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $359.19 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $344.40 | 2019-2025 | |
| Amgen INC. | $231.69 | 2019-2025 | Evenity, Prolia, Repatha |
| Ascensia Diabetes Care US INC. | $195.38 | 2022-2025 | |
| Radius Health, INC. | $181.18 | 2019-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $151.31 | 2021-2025 | |
| Pfizer INC. | $133.85 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $113.52 | 2024-2025 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.33 | 2022-2024 | Synjardy, Jardiance, Tradjenta |
| Xeris Pharmaceuticals, INC. | $102.22 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $99.38 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $91.83 | 2019-2025 | |
| Insulet Corporation | $87.66 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73.80 | 2021-2024 | Vraylar |
| Sumitomo Pharma America, INC. | $61.83 | 2023 | Gemtesa |
| Antares Pharma, INC. | $56.20 | 2019-2020 | |
| Kyowa Kirin, INC. | $48.28 | 2023-2024 | Crysvita |
| Averitas Pharma INC. | $47.45 | 2024-2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $42.07 | 2023-2024 | Rexulti |
| Dexcom, INC. | $41.31 | 2022-2023 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $39.06 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $37.08 | 2024 | |
| Amryt Pharma Holdings LTD | $35.27 | 2022-2023 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $34.10 | 2022-2023 | Strensiq |
| Mannkind Corporation | $29.53 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $25.64 | 2019-2023 | Belsomra |
| Actelion Pharmaceuticals US, INC. | $24.52 | 2024 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $24.05 | 2019 | |
| Amarin Pharma, INC. | $20.99 | 2019 | |
| Astellas Pharma US INC | $20.38 | 2024 | Veozah |
| Ultragenyx Pharmaceutical INC. | $19.27 | 2023 | |
| Neurocrine Biosciences, INC. | $18.80 | 2025 | |
| Exact Sciences Corporation | $16.23 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $15.36 | 2021 | |
| Chiesi USA, INC. | $14.74 | 2024 | Mycapssa |
| Glaxosmithkline, LLC. | $13.15 | 2023 | Shingrix, Arexvy |
| Valeritas, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsen Zena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.